All In Biotech

Drug Trial Radar · NCT07789015

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

A Phase III, Parallel Design, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial to Evaluate the Efficacy and Safety of Nerandomilast Oral Therapy Added to Standard Background Therapy Over 52 Weeks in Adult Trial Participants With Active Idiopathic Inflammatory Myopathies (VERANDA™-IIM)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Dec 14, 2026

Primary completion

Mar 21, 2030

Study completion Apr 4, 2030

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults aged 18 and older who have a condition known as active idiopathic inflammatory myopathy (IIM) or myositis. People can participate if they have a specific type of myositis. The purpose of this study is to find out whether a medicine called nerandomilast improves IIM symptoms. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take nerandomilast or placebo twice a day for 1 year. Participants are in the study for about 1 year and 2 months. During this time, they visit the study site at least 16 times. During this time, doctors regularly check the participant's health, IIM symptoms, and take note of any unwanted effects. Participants fill in questionnaires about their IIM symptoms and how IIM impacts their quality of life. The results are compared between the 2 groups to see whether the treatment works.

Conditions

  • Idiopathic Inflammatory Myopathies

Interventions

  • PlaceboDrug

    Placebo-matching nerandomilast

  • NerandomilastDrug

    Nerandomilast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total improvement score (TIS) score (continuous) at Week 52Time frame: At Week 52.

Locations

160 sites in 26 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Scottsdale, Arizona

  • University of California Irvine

    Irvine, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California San Francisco

    San Francisco, California

  • University of Colorado Denver

    Aurora, Colorado

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Kansas University Medical Center

    Fairway, Kansas

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Northwell Health

    Great Neck, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Paramount Medical Research and Consulting

    Middleburg Heights, Ohio

  • Oregon Health & Sciences University

    Portland, Oregon

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • West Tennessee Research Institute

    Jackson, Tennessee

  • Helios CR, Inc - Dallas

    Dallas, Texas

  • Nerve and Muscle Center of Texas

    Houston, Texas

  • The University of Texas Health Science Center at Houston

    Houston, Texas

  • Bioclinic Research

    C.a.b.a, Argentina

  • Centro Argentino de Investigacion (CADI)-Diagnostico Medico

    CABA, Argentina

  • Instituto de Investigacion Clinica TyT

    CABA, Argentina

  • Instituto Medico Especializado

    Capital Federal, Argentina

  • Framingham Centro Medico

    La Plata, Argentina

  • Instituto Medico CER

    Quilmes, Argentina

  • Sanatorio de la Mujer

    Rosario, Argentina

  • Centro de Investigaciones Medicas Tucuman

    San Miguel de Tucumán, Argentina

  • Alto Dorrego Consultorios

    Villa Nueva, Argentina

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia

  • Wollongong Hospital

    Wollongong, New South Wales, Australia

  • Austin Health

    Ivanhoe, Victoria, Australia

  • Perron Institute

    Nedlands, Western Australia, Australia

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitair Ziekenhuis Brussel

    Jette, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Centre Hospitalier Universitaire de Liège

    Liège, Belgium

Showing 40 of 160 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.